-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target

Benzinga·06/12/2026 14:04:54
Listen to the news
Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $31 price target.